Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.
about
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsExtended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to VemurafenibDetermination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer.Autophagy: A potential target for thyroid cancer therapy (Review)Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsMultikinase inhibitors use in differentiated thyroid carcinoma.Molecular profiling of thyroid cancer subtypes using large-scale text mining.Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer TreatmentsMicroRNA expression profiles in differentiated thyroid cancer, a reviewSubgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerControversies in the management and followup of differentiated thyroid cancer: beyond the guidelines.A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentPopulation pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancerThyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.Lenvatinib: A Review in Refractory Thyroid Cancer.Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study.Papillary thyroid carcinoma expressing CD20.Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer.Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.Prolonged duration of response in lenvatinib responders with thyroid cancer.
P2860
Q26863326-D1ACD6D0-8D7F-4504-AD71-B7DCF5D1268FQ27853034-60310D47-0E0B-4158-B860-A706D9B2B5D7Q31114848-41BCDEBA-7EF4-429A-AC3E-E3148A994701Q33933013-3E1CF6A5-0538-4901-916F-4298873D5E82Q34253418-B0E56864-B738-4C65-9AAA-E4346F869E37Q34660901-56B925B9-4193-4AA8-965E-5B14B7498684Q34914970-965C83C7-3D70-46A6-AFF4-036516CB03CDQ35876617-A5778DFA-C646-4F22-9B2B-9BFF2567B750Q36030561-28AE0C6B-8B14-42B3-A6B9-D460700B8E66Q36366960-98C37F1C-1D54-413B-83B6-75B093A8A680Q36449793-5CA4E3A2-B6EB-4CFD-B1C9-4E64483B03C9Q36467394-2B4DC181-FC08-4BBD-9B6E-7A072DDDD00AQ36530119-7D126EAC-1B3B-4938-8B47-669089A86C84Q36716739-5986EDB4-0952-45B1-A0E0-FAA983C90E61Q36924717-3F097FFA-CB9B-4193-8142-99FA99DDDD06Q37010592-8F6B6C60-B877-4AA4-B891-CA1526A4C60CQ37665265-2C5E3E24-69BC-4670-AC74-42279E9B4D38Q38729953-D11A951D-DA76-4787-A151-CD046DBCDA61Q44819667-2F3D0AAB-3F7C-4A99-BAD9-02B506A3C2FFQ47114573-0B4615C6-3E4D-4337-808F-1E6B65D679AEQ50583371-2ED1E159-3CC6-4090-8BEE-72C36F90E709Q50943856-254E8976-3CC7-4BDD-9921-63CD4211FA27Q53109364-AC88A731-EE74-493A-8A72-F4AEC3657735Q55413273-1A1E2B1C-D5C3-4872-ABB2-4299C75A6A94
P2860
Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@ast
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@en
type
label
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@ast
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@en
prefLabel
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@ast
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@en
P2860
P356
P1476
Differentiated thyroid cancer: ...... oiodine nonresponsive disease.
@en
P2093
Maria E Cabanillas
Naifa Lamki Busaidy
P2860
P304
P356
10.1155/2012/618985
P577
2012-02-28T00:00:00Z